Spots Global Cancer Trial Database for enzastaurin
Every month we try and update this database with for enzastaurin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | NCT00451178 | Lymphoma | enzastaurin rituximab cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - | Eli Lilly and Company | |
| Enzastaurin Versus Lomustine in Glioblastoma | NCT00295815 | Glioblastoma | enzastaurin lomustine | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | NCT00452413 | Non-Small Cell ... Malignant Solid... | enzastaurin erlotinib | 18 Years - | Eli Lilly and Company | |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | NCT00586508 | Recurrent Gliob... | enzastaurin bevacizumab Enzyme-inducing... Non-enzyme indu... | 18 Years - | Eli Lilly and Company | |
| An Open Label Study of Oral Enzastaurin in Participants With Cancer | NCT00309140 | Neoplasms Cancer | enzastaurin | 18 Years - | Eli Lilly and Company | |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | NCT00586508 | Recurrent Gliob... | enzastaurin bevacizumab Enzyme-inducing... Non-enzyme indu... | 18 Years - | Eli Lilly and Company | |
| Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | NCT00536939 | Breast Cancer | Enzastaurin Bevacizumab Paclitaxel Placebo | 18 Years - | Eli Lilly and Company | |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin | NCT01388335 | Solid Tumor Lymphoma, Malig... | warfarin enzastaurin | 18 Years - 60 Years | Eli Lilly and Company | |
| Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | NCT00533429 | Non-small Cell ... | enzastaurin pemetrexed carboplatin bevacizumab Placebo | 18 Years - | Eli Lilly and Company | |
| Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | NCT03263026 | Diffuse Large B... | Enzastaurin Hyd... R-CHOP + placeb... | 18 Years - | Denovo Biopharma LLC | |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin | NCT01388335 | Solid Tumor Lymphoma, Malig... | warfarin enzastaurin | 18 Years - 60 Years | Eli Lilly and Company | |
| A Study of Enzastaurin in Participants With Follicular Lymphoma | NCT00475644 | Lymphoma, Folli... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | NCT00267020 | Pancreatic Neop... | enzastaurin gemcitabine | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | NCT00452413 | Non-Small Cell ... Malignant Solid... | enzastaurin erlotinib | 18 Years - | Eli Lilly and Company | |
| Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | NCT00267020 | Pancreatic Neop... | enzastaurin gemcitabine | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin in Participants With Follicular Lymphoma | NCT00475644 | Lymphoma, Folli... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | NCT00586508 | Recurrent Gliob... | enzastaurin bevacizumab Enzyme-inducing... Non-enzyme indu... | 18 Years - | Eli Lilly and Company | |
| Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | NCT00437294 | Breast Cancer | enzastaurin placebo capecitabine | 18 Years - | Eli Lilly and Company | |
| Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma | NCT00088205 | Mantle-Cell Lym... | enzastaurin | 18 Years - | Eli Lilly and Company | |
| Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | NCT00538681 | Lung Cancer | enzastaurin pemetrexed cisplatin placebo | 18 Years - | Eli Lilly and Company | |
| First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00308750 | Non-Small Cell ... | enzastaurin pemetrexed docetaxel carboplatin | 18 Years - | Eli Lilly and Company | |
| An Open Label Study of Oral Enzastaurin in Participants With Cancer | NCT00309140 | Neoplasms Cancer | enzastaurin | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma | NCT01432951 | Solid Tumor Lymphoma, Malig... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers | NCT00414960 | Lung Cancer | Enzastaurin Placebo | 45 Years - | Eli Lilly and Company | |
| Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | NCT00533429 | Non-small Cell ... | enzastaurin pemetrexed carboplatin bevacizumab Placebo | 18 Years - | Eli Lilly and Company | |
| Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | NCT00538681 | Lung Cancer | enzastaurin pemetrexed cisplatin placebo | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma | NCT01432951 | Solid Tumor Lymphoma, Malig... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | NCT00536939 | Breast Cancer | Enzastaurin Bevacizumab Paclitaxel Placebo | 18 Years - | Eli Lilly and Company | |
| Chemotherapy for Participants With Lymphoma | NCT00436280 | Lymphoma, Large... | enzastaurin gemcitabine rituximab oxaliplatin | 60 Years - | Eli Lilly and Company | |
| A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | NCT00466440 | Prostate Cancer | enzastaurin placebo docetaxel prednisone | 18 Years - | Eli Lilly and Company | |
| A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | NCT00466440 | Prostate Cancer | enzastaurin placebo docetaxel prednisone | 18 Years - | Eli Lilly and Company | |
| A Study for Patients With Non-Hodgkin's Lymphomas | NCT00542919 | T-Cell Lymphoma B-Cell Lymphoma | enzastaurin | 18 Years - | Eli Lilly and Company | |
| A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | NCT00437268 | Colorectal Canc... Colorectal Carc... Colorectal Tumo... | enzastaurin irinotecan cetuximab | 18 Years - | Eli Lilly and Company | |
| An Open Label Study of Oral Enzastaurin in Participants With Cancer | NCT00309140 | Neoplasms Cancer | enzastaurin | 18 Years - | Eli Lilly and Company | |
| Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | NCT00391118 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | enzastaurin carboplatin paclitaxel placebo | 18 Years - | Eli Lilly and Company | |
| First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00308750 | Non-Small Cell ... | enzastaurin pemetrexed docetaxel carboplatin | 18 Years - | Eli Lilly and Company | |
| Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | NCT00538681 | Lung Cancer | enzastaurin pemetrexed cisplatin placebo | 18 Years - | Eli Lilly and Company | |
| Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | NCT00533429 | Non-small Cell ... | enzastaurin pemetrexed carboplatin bevacizumab Placebo | 18 Years - | Eli Lilly and Company | |
| A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | NCT00744991 | Cutaneous T-Cel... | Enzastaurin | 18 Years - | Eli Lilly and Company | |
| A Study of Enzastaurin in Patients With Leukemia | NCT00452257 | Leukemia, Lymph... | enzastaurin | 18 Years - | Eli Lilly and Company | |
| Chemotherapy for Participants With Lymphoma | NCT00436280 | Lymphoma, Large... | enzastaurin gemcitabine rituximab oxaliplatin | 60 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
